FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384207866> ?p ?o ?g. }

• W4384207866 endingPage "104881" @default.
• W4384207866 startingPage "104881" @default.
• W4384207866 abstract "Relapsing multiple sclerosis (MS) is an inflammatory, demyelinating, neurodegenerative disease of the central nervous system that causes episodes of neurological dysfunction (relapse) alternating with variable intervals of stability. Disease-modifying therapies (DMTs) aim to reduce the rate of relapse and slow disease progression in people with MS, particularly in those with relapsing MS. Ofatumumab is a fully human anti-CD20 monoclonal antibody approved to treat patients with relapsing forms of MS. This study describes the demographics, clinical characteristics, and prior DMT use of patients with at least one ofatumumab prescription claim following approval by the United States (US) Food and Drug Administration (FDA). Understanding ofatumumab utilization patterns and patient characteristics can help define the journey of patients with MS and aid future clinical decision-making.This retrospective study is based on data from IQVIA's Longitudinal Prescription Data (LRx) and Medical Claims (Dx) databases in the US, collected between August 01, 2019 and May 31, 2021. The index date was defined as the date of the first ofatumumab prescription. The pre-index period was defined as the 12 months prior to the index date. Adult patients (aged ≥18 years) with a diagnosis of MS and at least one prescription for ofatumumab between August 2020 and May 2021 in the LRx database were included. Only patients with at least one medical claim in the Dx database and a diagnosis of MS 24 months prior to the index date were included. Descriptive analyses were conducted 3, 6, and 9 months after FDA approval.Overall, 3,600 patients with a prescription for ofatumumab were identified in the LRx claims database, and 2,101 patients remained in the study after inclusion and exclusion criteria had been applied. At the 9-month post-approval time point, patients with ofatumumab claims were characterized as primarily female (74%) and middle-aged (median age: 48 years); two-thirds (64.7%) had a mild MS disability level. Patients were otherwise generally healthy with limited comorbid conditions. Most patients (81.7%) in the study did not experience relapse during the pre-index period. DMT-naïve patients who were prescribed ofatumumab at 3, 6, and 9 months post-approval accounted for 46.9%, 54.8%, and 58.4% of the study population, respectively. Over time, this increase in DMT-naïve ofatumumab initiators was statistically significant (p = 0.0003). Among patients who had been treated with DMTs during the previous year, most had taken them orally (50.6%), some had received them via intravenous infusion (32.2%), and some via subcutaneous/intramuscular injection (21.1%). Intravenous ocrelizumab was the most common DMT switch observed (n = 205, 23.4%) among these patients.This real-world study is the first to describe patients treated with ofatumumab since FDA approval during the COVID-19 pandemic. The majority of patients in this study were middle-aged women with mild MS symptoms. Ofatumumab was increasingly used as a first-line DMT. Additionally, a number of patients aged ≥55 years (beyond the trial population) used ofatumumab, which may suggest expanding clinician confidence in the safety and clinical utility of ofatumumab therapy. However, future long-term observational studies are needed to confirm these results." @default.
• W4384207866 created "2023-07-14" @default.
• W4384207866 creator A5012376027 @default.
• W4384207866 creator A5054726198 @default.
• W4384207866 creator A5056451668 @default.
• W4384207866 creator A5056720424 @default.
• W4384207866 creator A5061025039 @default.
• W4384207866 creator A5086265382 @default.
• W4384207866 creator A5088161063 @default.
• W4384207866 creator A5091357745 @default.
• W4384207866 date "2023-10-01" @default.
• W4384207866 modified "2023-10-01" @default.
• W4384207866 title "Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic" @default.
• W4384207866 cites W2014094373 @default.
• W4384207866 cites W2038054049 @default.
• W4384207866 cites W2916478209 @default.
• W4384207866 cites W2965263041 @default.
• W4384207866 cites W3021445393 @default.
• W4384207866 cites W3047302551 @default.
• W4384207866 cites W3099273656 @default.
• W4384207866 cites W3112098238 @default.
• W4384207866 cites W3193418223 @default.
• W4384207866 cites W3194394721 @default.
• W4384207866 cites W4200453726 @default.
• W4384207866 cites W4205276907 @default.
• W4384207866 cites W4220879604 @default.
• W4384207866 doi "https://doi.org/10.1016/j.msard.2023.104881" @default.
• W4384207866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37556938" @default.
• W4384207866 hasPublicationYear "2023" @default.
• W4384207866 type Work @default.
• W4384207866 citedByCount "0" @default.
• W4384207866 crossrefType "journal-article" @default.
• W4384207866 hasAuthorship W4384207866A5012376027 @default.
• W4384207866 hasAuthorship W4384207866A5054726198 @default.
• W4384207866 hasAuthorship W4384207866A5056451668 @default.
• W4384207866 hasAuthorship W4384207866A5056720424 @default.
• W4384207866 hasAuthorship W4384207866A5061025039 @default.
• W4384207866 hasAuthorship W4384207866A5086265382 @default.
• W4384207866 hasAuthorship W4384207866A5088161063 @default.
• W4384207866 hasAuthorship W4384207866A5091357745 @default.
• W4384207866 hasBestOaLocation W43842078661 @default.
• W4384207866 hasConcept C126322002 @default.
• W4384207866 hasConcept C203014093 @default.
• W4384207866 hasConcept C2426938 @default.
• W4384207866 hasConcept C2776036978 @default.
• W4384207866 hasConcept C2778714382 @default.
• W4384207866 hasConcept C2778843634 @default.
• W4384207866 hasConcept C2779134260 @default.
• W4384207866 hasConcept C2779338263 @default.
• W4384207866 hasConcept C2780640218 @default.
• W4384207866 hasConcept C2780653079 @default.
• W4384207866 hasConcept C2781004633 @default.
• W4384207866 hasConcept C3008058167 @default.
• W4384207866 hasConcept C524204448 @default.
• W4384207866 hasConcept C71924100 @default.
• W4384207866 hasConcept C89623803 @default.
• W4384207866 hasConcept C98274493 @default.
• W4384207866 hasConceptScore W4384207866C126322002 @default.
• W4384207866 hasConceptScore W4384207866C203014093 @default.
• W4384207866 hasConceptScore W4384207866C2426938 @default.
• W4384207866 hasConceptScore W4384207866C2776036978 @default.
• W4384207866 hasConceptScore W4384207866C2778714382 @default.
• W4384207866 hasConceptScore W4384207866C2778843634 @default.
• W4384207866 hasConceptScore W4384207866C2779134260 @default.
• W4384207866 hasConceptScore W4384207866C2779338263 @default.
• W4384207866 hasConceptScore W4384207866C2780640218 @default.
• W4384207866 hasConceptScore W4384207866C2780653079 @default.
• W4384207866 hasConceptScore W4384207866C2781004633 @default.
• W4384207866 hasConceptScore W4384207866C3008058167 @default.
• W4384207866 hasConceptScore W4384207866C524204448 @default.
• W4384207866 hasConceptScore W4384207866C71924100 @default.
• W4384207866 hasConceptScore W4384207866C89623803 @default.
• W4384207866 hasConceptScore W4384207866C98274493 @default.
• W4384207866 hasFunder F4320310388 @default.
• W4384207866 hasLocation W43842078661 @default.
• W4384207866 hasLocation W43842078662 @default.
• W4384207866 hasOpenAccess W4384207866 @default.
• W4384207866 hasPrimaryLocation W43842078661 @default.
• W4384207866 hasRelatedWork W1532617462 @default.
• W4384207866 hasRelatedWork W2059346471 @default.
• W4384207866 hasRelatedWork W2133920312 @default.
• W4384207866 hasRelatedWork W2272446420 @default.
• W4384207866 hasRelatedWork W2732823864 @default.
• W4384207866 hasRelatedWork W2959474424 @default.
• W4384207866 hasRelatedWork W3030177861 @default.
• W4384207866 hasRelatedWork W3206160011 @default.
• W4384207866 hasRelatedWork W4283511960 @default.
• W4384207866 hasRelatedWork W4376871081 @default.
• W4384207866 hasVolume "78" @default.
• W4384207866 isParatext "false" @default.
• W4384207866 isRetracted "false" @default.
• W4384207866 workType "article" @default.